Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

27.52  -0.83 (-2.93%)

After market: 27.52 0 (0%)

Fundamental Rating

3

Taking everything into account, APLS scores 3 out of 10 in our fundamental rating. APLS was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of APLS have multiple concerns. APLS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year APLS has reported negative net income.
In the past year APLS has reported a negative cash flow from operations.
APLS had negative earnings in each of the past 5 years.
APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M

1.2 Ratios

APLS has a Return On Assets of -27.73%. This is in the better half of the industry: APLS outperforms 71.05% of its industry peers.
APLS has a Return On Equity of -105.47%. This is comparable to the rest of the industry: APLS outperforms 44.76% of its industry peers.
Industry RankSector Rank
ROA -27.73%
ROE -105.47%
ROIC N/A
ROA(3y)-79.15%
ROA(5y)-70.33%
ROE(3y)-343.76%
ROE(5y)-418.16%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 86.47%, APLS belongs to the top of the industry, outperforming 89.88% of the companies in the same industry.
APLS's Gross Margin has declined in the last couple of years.
APLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
APLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for APLS has been increased compared to 5 years ago.
The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

APLS has an Altman-Z score of -0.73. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
APLS's Altman-Z score of -0.73 is fine compared to the rest of the industry. APLS outperforms 60.21% of its industry peers.
APLS has a Debt/Equity ratio of 1.91. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.91, APLS is doing worse than 82.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.91
Debt/FCF N/A
Altman-Z -0.73
ROIC/WACCN/A
WACC8.91%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M

2.3 Liquidity

APLS has a Current Ratio of 4.36. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
APLS has a Current ratio (4.36) which is comparable to the rest of the industry.
APLS has a Quick Ratio of 3.73. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
APLS has a Quick ratio (3.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 3.73
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

7

3. Growth

3.1 Past

APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.00%, which is quite impressive.
APLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 162.08%.
Measured over the past years, APLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.53% on average per year.
EPS 1Y (TTM)64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.68%
Revenue 1Y (TTM)162.08%
Revenue growth 3Y16.53%
Revenue growth 5YN/A
Sales Q2Q%78.29%

3.2 Future

The Earnings Per Share is expected to grow by 20.49% on average over the next years. This is a very strong growth
Based on estimates for the next years, APLS will show a very strong growth in Revenue. The Revenue will grow by 30.23% on average per year.
EPS Next Y61.27%
EPS Next 2Y33.36%
EPS Next 3Y29.52%
EPS Next 5Y20.49%
Revenue Next Year95.45%
Revenue Next 2Y48.35%
Revenue Next 3Y40.92%
Revenue Next 5Y30.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as APLS's earnings are expected to grow with 29.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.36%
EPS Next 3Y29.52%

More info and screens

0

5. Dividend

5.1 Amount

APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (2/21/2025, 8:01:27 PM)

After market: 27.52 0 (0%)

27.52

-0.83 (-2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)02-28 2025-02-28/bmo
Inst Owners103.98%
Inst Owner Change10.13%
Ins Owners4.12%
Ins Owner Change1.21%
Market Cap3.42B
Analysts80.71
Price Target47.02 (70.86%)
Short Float %16.22%
Short Ratio8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.56%
Min EPS beat(2)-50.27%
Max EPS beat(2)15.16%
EPS beat(4)2
Avg EPS beat(4)-6.91%
Min EPS beat(4)-50.27%
Max EPS beat(4)15.16%
EPS beat(8)4
Avg EPS beat(8)-4.45%
EPS beat(12)4
Avg EPS beat(12)-5.55%
EPS beat(16)5
Avg EPS beat(16)1.33%
Revenue beat(2)1
Avg Revenue beat(2)-0.61%
Min Revenue beat(2)-3.68%
Max Revenue beat(2)2.46%
Revenue beat(4)2
Avg Revenue beat(4)0.53%
Min Revenue beat(4)-3.68%
Max Revenue beat(4)3.42%
Revenue beat(8)5
Avg Revenue beat(8)12.93%
Revenue beat(12)8
Avg Revenue beat(12)56.95%
Revenue beat(16)10
Avg Revenue beat(16)45.84%
PT rev (1m)1.88%
PT rev (3m)0.22%
EPS NQ rev (1m)-1.47%
EPS NQ rev (3m)-1.47%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-1.23%
Revenue NQ rev (1m)3.16%
Revenue NQ rev (3m)3.16%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.79
P/FCF N/A
P/OCF N/A
P/B 14.44
P/tB 14.44
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.65
OCFYN/A
SpS5.75
BVpS1.91
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.73%
ROE -105.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.47%
FCFM N/A
ROA(3y)-79.15%
ROA(5y)-70.33%
ROE(3y)-343.76%
ROE(5y)-418.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5YN/A
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 1.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.1%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.36
Quick Ratio 3.73
Altman-Z -0.73
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)73.7%
Cap/Depr(5y)354.43%
Cap/Sales(3y)1.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.68%
EPS Next Y61.27%
EPS Next 2Y33.36%
EPS Next 3Y29.52%
EPS Next 5Y20.49%
Revenue 1Y (TTM)162.08%
Revenue growth 3Y16.53%
Revenue growth 5YN/A
Sales Q2Q%78.29%
Revenue Next Year95.45%
Revenue Next 2Y48.35%
Revenue Next 3Y40.92%
Revenue Next 5Y30.23%
EBIT growth 1Y62.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.58%
EBIT Next 3Y42.64%
EBIT Next 5Y33.17%
FCF growth 1Y57.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.75%
OCF growth 3YN/A
OCF growth 5YN/A